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Determination of the prevalence of accumulated antiretroviral drug resistance among persons infected with
human immunodeficiency virus (HIV) is complicated by the lack of routine measurement in clinical care. By using
data from 8 clinic-based cohorts from the North American AIDS Cohort Collaboration on Research and Design, drug-
resistance mutations from those with genotype tests were determined and scored using the Genotypic Resistance
Interpretation Algorithm developed at Stanford University. For each year from 2000 through 2005, the preva-
lence was calculated using data from the tested subset, assumptions that incorporated clinical knowledge, and
multiple imputation methods to yield a complete data set. A total of 9,289 patients contributed data to the analysis;
3,959 had at least 1 viral load above 1,000 copies/mL, of whom 2,962 (75%) had undergone at least 1 genotype
test. Using these methods, the authors estimated that the prevalence of accumulated resistance to 2 or more
antiretroviral drug classes had increased from 14% in 2000 to 17% in 2005 (P< 0.001). In contrast, the prevalence
of resistance in the tested subset declined from 57% to 36% for 2 or more classes. The authors’ use of clinical
knowledge and multiple imputation methods revealed trends in HIV drug resistance among patients in care that
were markedly different from those observed using only data from patients who had undergone genotype tests.
antiretroviral therapy, highly active; drug resistance; genotype; HIV
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; HIV, human immunodeficiency virus;
NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside-analogue reverse transcriptase inhibitor; PI, protease
inhibitor.
Missingness of data is a ubiquitous problem in epidemio-
logic studies and results from 2 primary causes. The first
contributor is lack of response, which can result from refusal
(nonresponse) or loss to follow-up (nonparticipation). Incom-
plete data may also occur structurally, such as when data
collection is determined by clinical-care decisions. Those
selected for a medical procedure, intervention, or test will
contribute data, whereas those not selected or indicated for
treatment will not. By definition, the selected sample will
differ clinically from those who do not receive the treatment.
Human immunodeficiency virus (HIV) drug resistance is
one area of research in which the amount of missing data is
heavily influenced by selection. Combination antiretroviral
therapy (ART) has been highly successful over the past de-
cade in reducing the morbidity and mortality associated with
HIV-1 infection (1) and restoring immunologic function (2).
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However, poor adherence (and subsequent virologic failure),
as well as extensive treatment exposures (particularly to
suboptimal treatment regimens), can result in acquired re-
sistance to both specific HIV drugs and entire drug classes
(3–5), limiting treatment options. Population trends in re-
sistance could thus be a primary motivator for the develop-
ment of new therapeutic agents and could be informative for
estimating the burden of uncontrolled disease and cost of
care. Furthermore, individuals with a resistant virus that is
uncontrolled by their current regimens will contribute to part
of a community viral load, one of the key metrics identified
in the 2010 National HIV/AIDS Strategy (6).
Most data available on drug resistance status arise from
genotype testing, that is, genotyping of sampled HIV strains
to detect mutations that confer drug resistance. These tests
have several characteristics that complicate analysis of even
simple prevalence descriptions. First, standard laboratory tests
measure only genotypic resistance among subjects with a high
viral load. As a consequence, individuals who undergo geno-
type testing likely differ clinically from those who do not.
Second, Department of Health and Human Services guide-
lines recommend that these resistance tests be used to guide
the choice of ART for those who may be failing to respond
to other therapies. Third, characterization of HIV drug re-
sistance is complicated by the impact of changing drug
regimens on circulating viral strains. Therapies will sup-
press but not eradicate an established viral strain. Such
archived resistance cannot be detected by genotype testing
with commercial assays but contributes to the overall burden
of drug resistance because it influences treatment options
and effectiveness (7).
To estimate of the prevalence of latent and circulating
resistance among treated populations in clinical care, ap-
proaches should be used that address the noted selection
and missing data issues. Unfortunately, the majority of stud-
ies that have assessed the burden of resistance made infer-
ences using only data from individuals who had undergone
genotype tests in the course of clinical care. It is well known
that the complete case analysis approach can lead to bias
and diminished precision (8–10).
In the present article, we describe methods to yield
resistance-prevalence inferences for individuals who are in
clinical care and engaged in treatment. Our approach centers
around the idea of completing missing resistance status data
by incorporating clinical knowledge of the influences of
many factors (e.g., patient drug history, viral load trajectory,
and past genotype testing information) on an individual’s re-
sistance probability. Multiple-imputation methods (11) alone
could be utilized to obtain an asymptotically unbiased es-
timate of the prevalence of resistance if missingness could
be assumed random, conditional on factors measured and
available to the investigator (11). However, it is unlikely that
missingness of data will be conditionally independent of a
strain’s being resistant, given what is known of HIV biology.
For example, adherence measurements are not commonly
available; however, a patient with an extensive history of
poor adherence might be both less likely to have been tested
(because modifying the existing regimen might not be ben-
eficial until adherence is improved) and more likely to harbor
resistance (unless adherence declines below the threshold at
which there is no selective pressure on the virus to induce a
resistant strain to emerge). Given that current clinical guide-
lines specify the consideration of factors such as drug and
viral load history, as well as resistance testing in the optimi-
zation of therapy (12) (as this information best informs clin-
ical judgment as to the potential for archived resistance and
thus a therapy’s effectiveness), incorporating such clinical
understanding into a data-completion algorithm could offer




The North American AIDS Cohort Collaboration on Re-
search and Design (NA-ACCORD) is a consortium of clin-
ical and interval HIV cohorts from Canada and the United
States (13). It is 1 of 7 regional collaborations of the Interna-
tional Epidemiologic Databases to Evaluate AIDS that are
supported by the National Institutes of Health. Genotype test-
ing data were collected from 8 clinic-based cohorts within the
NA-ACCORD during the period of interest (2000–2005),
and those centers agreed to participate in the present anal-
ysis. We identified those individuals who had initiated ART
before 2006 and had at least 1 clinic visit between 2000 and
2006. Participants contributed only to estimates in years in
which they were actively followed (seen in the clinic at least
once), as inferences were targeted at the population engaged
in clinical care. Cohorts contributed data on specific geno-
typic resistance mutations identified by using tests conducted
as part of clinical care. We included viral load information
from participants with genotypic data if an HIV-1 RNA
measurement was available in the 6 months before the ge-
notype test.
Study definitions and design
There are currently 5 distinct classes of antiretroviral drugs
available to HIV-infected individuals in developed countries.
These drugs include nucleoside-analogue reverse transcriptase
inhibitors (NRTIs), protease inhibitors (PIs), nonnucleoside
reverse transcriptase inhibitors (NNRTIs), fusion inhibitors,
and integrase inhibitors. Effective antiretroviral therapies rely
on a combination of drugs, preferably from a mix of different
classes. Here, we focus on the 3 major classes of drugs
(PIs, NNRTs, and NRTIs) that have been available since the
late 1990s. We defined ARTas a regimen including 2 or more
NRTIs with at least 1 PI or NNRTI. Triple NRTI regimens
with abacavir or tenofovir were also included.
Genotype mutations were analyzed using the Genotypic
Resistance Interpretation Algorithm, version 4.3.6 (HIVdb
Program, Stanford University, Stanford, California), which
assigns inferred levels of resistance to commonly used PIs
and RTIs on the basis of user-submitted protease and RT gene
sequences (14). Genotypic resistance to any single drug was
considered present if the algorithm assigned a score of 30
(‘‘intermediate resistance’’) or higher for the occurrence of a
given mutation pattern. We defined ‘‘class’’ resistance as in-
termediate or higher resistance to any single drug in any given
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therapeutic drug class available at the time of the genotype
test. Because HIV-1 RNA undergoes reverse transcription into
DNA and is inserted into the host cell’s DNA, various HIV
mutations are considered to be archived into the latent reser-
voir (7). Therefore, resistance mutations were considered to
accumulate over time and were carried forward, with new re-
sistance tests maintaining or increasing resistance scores from
previous years. If results from more than 1 test were available
for an individual in a given year, the scores from the last test
in that year (representing the cumulative scores from all past
tests) were used. Participants were considered to have viremia
in a given year if they had at least 1 HIV-1 RNAmeasurement
higher than 1,000 copies/mL after 3 continuous months on an
initial antiretroviral regimen. Because genotype testing re-
quires a high viral load for reliable results, we also considered
genotype testing of a marker of viremia in the year of the test.
Covariate data for those tested were taken from the visit clos-
est to the date of the test within the previous 6 months. For
participants for whom we did not have testing data, covariate
information was used from the last visit with viremia (in those
with viremia in a given year) or the last visit in the year
(in those without viremia in a given year). These time points
were selected to provide the participant with the maximum
opportunity to receive genotype testing (in the former case) or
become viremic (in the latter case).
Statistical analysis
Estimates of the prevalences of accumulated 2- and 3-class
resistance were obtained by creating a complete data set of
individual resistance probabilities for each calendar year
between 2000, when genotypic resistance testing became
widely available in the clinic setting, and 2005. Current sci-
entific understanding regarding the persistence of resistant
viral strains and the clinical context for the development of
resistance were applied to complete the missing data as fol-
lows. The accumulated 2- and 3-class-resistance data from
the subset of the cohort for whom we had genotypic testing
information were extended forward in time with the assump-
tion that resistance was present indefinitely (because of the
archival nature of the HIV virus). Thus, in years in which the
participant was seen (contributed viral load data) but did not
undergo a genotype resistance test, any past level of accumu-
lated resistancewas considered still to be present. Participants
with no previous testing information who were virally sup-
pressed (i.e., had HIV-1 RNA levels 1,000 copies/mL) in a
given year were assumed to have no resistance in that year.
Similarly, participants with viremia who later demonstrated
suppression on an NNRTI or PI regimen were assumed to
have accumulated no resistance to those drug classes. For the
remaining participant-years with viremia but unknown resis-
tance status, we used the multiple-imputation method (11) to
estimate the probability of resistance. Five imputation data
sets were created using a single-chain Markov chain Monte
Carlo method with the following covariates as main terms:
most recent HIV-1 RNA level and CD4þ cell count, history of
injected drug use, age, prior NRTI use before ART initiation,
cumulative exposure to each drug class, cumulative number
of past regimen failures, cohort, year of genotype test, race,
and sex. The model was fitted only in viremic participants
because covariate associations were found to vary by viremia
status. An expectation-maximization algorithm was used to
find the posterior mode as the starting value for the chain. The
final multiclass resistance prevalence estimates were deter-
mined as the average of the estimates resulting from the 5
imputation data sets. The process used to complete the data is
illustrated schematically in Figure 1.
The probability of having accumulated resistance (the
prevalence of accumulated resistance in the cohort) was
estimated for each year in all included participants who
were seen in that year. The trend in the yearly estimates
was assessed by regressing the individual resistance values
on the year and evaluating the significance and direction of
the slope. Confidence intervals were obtained by adding the
within-imputation and between-imputation variability. All
analyses were performed using SAS, version 9.2 (SAS In-
stitute, Inc., Cary, North Carolina).
RESULTS
Cohort virologic response
The analysis included 9,289 patients who participated in
1 of 8 clinic-based cohorts and who initiated ART before the
end of 2005 and underwent HIV-1 RNA testing in 2000–
2005. Of these patients, 3,959 (43%) had at least 1 HIV-1
RNA level greater than 1,000 copies/mL after at least 3
months of an initial therapy, and 2,962 (75% of those with
viremia) had at least 1 genotype resistance test performed.
In 2000, a total of 5,004 patients treated with antiviral drugs
had at least 1 strain of HIV-1 RNA measured; of these, 1,480
(30%) had at least 1 HIV-1 RNA level above 1,000 copies/mL
after at least 3 months of therapy and 817 (16% of the total
participants and 55% of those with viremia) underwent ge-
notype resistance testing (Table 1). In 2005, a total of 4,653
participants who had been treated with antiretroviral drugs
had at least 1 HIV-1 RNA level measured; of these, 778 (17%)
had at least 1 HIV-1 RNA level above 1,000 copies/mL after
at least 3 months of therapy and 486 (10% of the total
participants and 62% of those with viremia) underwent ge-
notype testing (Table 1). The proportion of treated patients
who had an HIV-1 RNA level above 1,000 copies/mL de-
clined over time (P < 0.001), as has been previously noted
(15–18). The percentage of individuals who had genotype
resistance testing out of the total number of patients on ART
declined from 2000 to 2005 (P < 0.001), whereas the per-
centage of those tested out of the total number with viremia
increased (P < 0.001).
Missing resistance status
Comparing those participants who did and did not have
genotype testing among the participants at risk for testing
(HIV-1 RNA levels >1,000 copies/mL; Table 2), we found
that those receiving genotype testing had lower median
HIV-1 RNA levels at the time of the test than did those who
were viremic but not tested in both 2000 and 2005. Those
tested in 2000 were less likely to have received NRTIs be-
fore their first combination therapy regimen (57% vs. 69%)
than were those whowere viremic but not tested in that same
Missing Data in the Estimation of ART Resistance 729
Am J Epidemiol. 2011;174(6):727–735
year. In both 2000 and 2005, those not tested were more
likely to report lapses in their ART regimen during the year.
Median CD4þ cell counts and ages were approximately the
same across testing groups. Race (white vs. nonwhite), sex,
and injection drug use (yes vs. no) distributions were also
similar between those tested and those not tested in a given
year.
Of 29,905 participant-years, we were missing genotype
data for 25,774. However, only 11% were person-years with
unsuppressed viral loads. Of this, 9%, 7%, 6%, 5%, 4%, and
Table 1. Frequency of Detectable Viremia and Genotype Testing Among Patients Treated With Antiretroviral



































% of No. With
Viremiaa
2000 5,004 1,920 38 1,387 28 1,480 30 817 16/55
2001 5,093 1,850 36 1,552 30 1,318 26 735 14/56
2002 5,063 1,767 35 1,627 32 1,360 27 781 15/57
2003 5,052 1,778 35 1,688 33 1,160 23 692 14/60
2004 5,040 2,035 40 1,614 32 986 20 620 12/63
2005 4,653 1,817 39 1,254 27 778 17 486 10/62
a P < 0.05 for comparisons across calendar year by Cochran-Armitage trend test.
4,131 Participant-years 
with genotype testing 
Genotypic Resistance 
Interpretation Algorithm  
version 4.3.6 
Resistance defined as 
intermediate or higher score; 




2,951 Viremic (viral load >1000 
copies/mL) participant-years with no 
genotype testing 
For remaining missing data, multiple 
imputation using participant 
characteristics (viral load, CD4+ cell 
count, injected drug use, age, prior 
NRTI use before ART initiation, cohort, 
year of test, race, sex, past ART 
exposure, past failures )  
Adjustments based on regimen data, 
viremia history, and assumption of 
persistence of past levels of resistancePrevalence of accumulated 
resistance in the cohort 
22,823 Suppressed (viral load 
≤1,000 copies/mL) participant-
years 
Remaining missing resistance 
probabilities assigned a 
resistance probability of zero. 
Missing resistance probabilities 
completed using past and future 
known values assuming that 
resistance, once acquired, 
persists. 
29,905 Participant-years 
after ART initiation 
Missing resistance probabilities 
completed using past and future 
known values assuming that 
resistance, once acquired, 
persists. 
Figure 1. Diagram illustrating the use of clinical knowledge in conjunction with themultiple-imputationmethod to completemissing data on human
immunodeficiency virus drug resistance status, North American AIDS Cohort Collaboration on Research and Design, 2000–2005. ART, antire-
troviral therapy; NRTI, nucleoside-analogue reverse transcriptase inhibitor.
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5% of the data on the accumulation of 2 or more classes of
resistance remained missing for years 2000 through 2005,
respectively, after the algorithm based on clinical knowledge
was applied to complete the data. Following the multiple-
imputation method to complete the remaining missing re-
sistance data, the relative increase in variance (as a result of
the remaining missingness) was estimated to be 2% and the
relative efficiency of the imputation estimator based on the
5 imputation data sets was 99%. Results were similar for
3-class resistance data.
Class resistance over time
When data from those in the cohort with missing geno-
type testing were ignored, the observed prevalence of class
resistance to 2 or more antiretroviral drug classes decreased
(P < 0.001 for trend; Table 3). The observed prevalences in
the tested subgroup were 57%, 56%, 49%, 34%, 37%, and
36% for the years 2000–2005, respectively. Likewise, the
observed prevalence of class resistance to 3 antiretroviral
drug classes declined over time (22% and 17% in 2000 and
2005, respectively; P < 0.001 for trend). The level of ob-
served wild-type (i.e., those without any detected drug re-
sistance) remained stable, at 12% in 2000 and 13% in 2005.
When combining estimated resistance (in those who were
viremic but not tested) with observed resistance (in those
who were tested), we found that the prevalence of accumu-
lated resistance in the entire cohort was much lower than the
observed prevalence in those with testing. There was a slight
increase in the estimated accumulated prevalence over time,
mostly from 2000 to 2001 (P< 0.001 for trend; Table 3). We
estimated the prevalences of accumulated resistance to 2 or
more classes to be 14%, 17%, 18%, 17%, 17%, and 17% for
the years 2000 through 2005, respectively. The prevalence of
accumulated 3-class resistance also slightly increased from
6% in 2000 to 7% in 2005 (P ¼ 0.008).
Sensitivity analyses
Incorporation of best clinical knowledge accounted for
the completion of 93% of the missing data and had the largest
impact on estimates of the prevalence of resistance. When
the algorithm for completing missing data using clinical
knowledge was ignored and the multiple-imputation method
was used as the sole means of completing the missing data,
the estimates for the prevalence of accumulated resistance to
2 or more classes of drugs in the cohort were 51%, 61%,
64%, 64%, 65%, and 66% for 2000–2005, respectively. The
estimates for the prevalence of accumulated 3-class resis-
tance in the cohort were 32%, 41%, 45%, 46%, 48%, and
50%, respectively. In contrast, using only clinical knowl-
edge to complete missing data and ignoring the remaining
missingness resulted in lower estimates for the prevalence.
For example, the prevalences of accumulated resistance
to 2 or more classes of drugs were estimated to be 10%,
13%, 15%, 14%, 14%, and 14% and to 3 classes were esti-
mated to be 4%, 5%, 5%, 5%, 5%, and 5% for 2000–2005,
respectively.
Regimen and viral load data were used to inform individ-
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information. However, future suppression on a PI or NNRTI
regimen does not fully exclude the possibility of resistance to
those classes. Excluding the regimen information resulted in
minor upward shifts of the estimated prevalences of 1%–2%.
DISCUSSION
In the present article, we used a modified multiple-
imputation method that augmented the statistical approach
with current clinical and scientific knowledge. The application
of this method to the study of antiretroviral drug resistance
enabled us to consider a large body of clinical knowledge
concerning archiving of resistance, drug cross-class resistance,
and future likelihood of viral suppression. The evolving ep-
idemiology of antiretroviral drug resistance in clinical prac-
tice has not been fully described, as inferences have relied
on data from resistance tests performed during the course of
routine clinical practice. Thus, a large percentage of missing
data has been routinely ignored in studies characterizing the
magnitude and trends in resistance. By estimating the prev-
alence of accumulated resistance using data from a represen-
tative sample of North American patients who had been
treated in clinical care, we found contrasting inferences re-
garding the trend in 2- and 3-class resistance compared
with those in the genotype-tested subset. The prevalences
of 2- and 3-class resistance in the entire cohort remained
essentially stable except in 2000, which accounted for the
significant trend test. This trend, compared with the dra-
matic decreases in class resistance observed among the tested
subset, speaks to 2 factors: first, the inability of testing to
capture the persistence of mutant viral strains in the latent
reservoir, and second, selection factors that determine who is
tested. Although the observed estimates do attempt to correct
for the latent reservoir by summing past resistance scores
over repeated tests, patients whowere subsequently doing well
on therapy (with a suppressed viral load) after a past failure did
not undergo subsequent tests. Using the methods presented
here, we were able to infer the likely resistance level for such
individuals based on their past testing results (e.g., PI-class
resistant in 2000), an assumption of archived resistance
(e.g., PI-class resistant in all subsequent years), and knowl-
edge of their viral load trajectory (e.g., suppressed viral load
since 2000 and thus no additional acquired resistance). Such
scientific knowledge regarding the development and persis-
tence of resistance took precedence over a random draw
from a multivariate normal distribution for completing the
missing resistance data.
The results using data from the subset of individuals who
underwent genotype resistance testing were generally consis-
tent with trends observed in several recent European cohorts
(13, 19–21). This apparent decline in resistance in the subset
of genotyped patients could be attributed to several factors,
including an earlier use of genotype testing among those fail-
ing to respond to ART (22), low adherence to the prescribed
therapeutic regimen (23–25), or the increased use of regimens
that are less likely to select for drug resistance (23, 26). All of
these factors could affect the percentages of mutations de-
tected in the circulating virus. Comparisons between those
who did and did not undergo genotype testing revealed clear
contrasts that suggested that inferences concerning resis-
tance trends cannot be extrapolated from the tested subco-
hort to the clinical-care population. Further, testing results
alone do not capture the reservoir of archived resistance in
the larger cohort of HIV-infected patients (unless repeated
frequent testing is used throughout follow-up). The multiple
imputation method, along with assumptions about the struc-
ture of the resistance data, provided 1 potential methodo-
logical approach to quantifying the burden of resistance in
the population over time in lieu of universal repeated testing
data. It should be noted that this approach still requires con-
ditional independence to hold in the partially completed data
(after clinical knowledge-based imputation) (10, 27). The val-
idity of the individual resistance probability estimates for those
not tested relies upon the predictive strength of the covariates
Table 3. Prevalence of 2- and 3-Class Resistance by Year Comparing Patients Who Underwent Human Immunodeficiency Virus Genotype
Testing With the Entire Cohort, North American AIDS Cohort Collaboration on Research and Design, 2000–2005
Year
Prevalence of Observed Resistance in Those
With Resistance Testing
Prevalence of Accumulated Resistance in Entire Cohort
Estimated Using Multiple Imputation Methods












% 95% CI % 95% CI % 95% CI % 95% CI
2000 57 53, 60 22 19, 25 14 13, 15 6 5, 7
2001 56 52, 59 22 19, 25 17 16, 18 7 7, 8
2002 49 45, 53 17 14, 20 18 17, 19 8 7, 9
2003 34 30, 38 16 13, 18 17 16, 18 8 7, 9
2004 37 33, 41 17 14, 19 17 16, 18 7 7, 8
2005 36 32, 41 17 14, 21 17 16, 18 8 7, 9
Abbreviation: CI, confidence interval.
a Classes refers to the 3 main antiretroviral therapy drug classes: nucleoside-analogue reverse transcriptase inhibitors, protease inhibitors,
and nonnucleoside reverse transcriptase inhibitors.
b P < 0.05 by Cochran-Armitage trend test.
c P < 0.05 for parameter estimate from the linear regression of prevalence on year.
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included in the multiple-imputation model, which may not
comprise the optimal set of explanatory factors. In the present
example, however, only approximately 6% of the data arose
from multiple-imputation models as a result of our use of
clinical knowledge to inform the data completion.
The greatest influence on the estimated prevalences and
subsequent trend arose from the integration of current scien-
tific knowledge about resistance. In particular, the assumption
concerning the persistence of resistant strains in an individual
over time defined a data structure that treated resistance as
a monotonically increasing function. The assumption that
despite a positive response to new regimens and an absence
of detectable drug-resistant viremia, an individual continues
to harbor resistant viral strains reflects current understand-
ing and evidence (28) and was incorporated into methods
used to compute both the observed prevalence and the esti-
mated cohort prevalence, though it was much more influen-
tial on cohort inferences for which the assumed structure
was used to complete missing data. Thus, the prevalence of
resistance we observed in any year was likely higher than
what would be expected from a cross-sectional survey of
resistance. However, because the earliest genotype testing
data we have are from 1997, the accumulation of resistance
only pertains to resistance captured after this time. Further,
resistant variants fade as selective pressure is removed, such
as during a period of poor or interrupted adherence to ther-
apeutic regimens. Therefore, our estimates of the prevalence
of accumulated resistance likely represent a lower bound for
the true prevalence.
A limitation of the analysis was the simplifying assumption
that genotype testing results, when available, were an accurate
reflection of phenotypic drug susceptibility. Genotype tests
have a limited ability to detect resistant circulating strains
at low viral loads and thus might result in falsely classifying
an individual as not harboring resistant viral strains. Of addi-
tional concern are tests that are administered after therapy has
been discontinued. With selective pressure no longer present,
resistant HIV strains may be undetectable at the time of the
test. Such misclassification of resistance status among the
tested through either mechanism would have affected both
the observed and accumulated prevalence estimates and re-
sulted in underestimation of the true prevalence of multiclass
resistance.
Of further interest is the generalizability of the estimates
presented. The target population in this study was HIV-
infected individuals engaged in clinical care. The source pop-
ulation was an open cohort of participants initiating ART
treatment who were observed during the year for which they
contributed to the prevalence estimate. We capture primarily
the burden of acquired resistance arising from treatment expo-
sure. The overall pool of resistance also includes community-
acquired resistance, which could not be adequately addressed
in the present study because of the limited numbers of pre-
ART genotype tests. The prevalence of community-acquired
multiclass resistance in North America is estimated to be
6%–17% (29, 30).
Patients who exhibit virologic failure (the result of either
nonadherence or resistance) on antiretroviral therapy tend to
have worse long-term outcomes than do those who achieve
durable viral suppression (3, 31–36). The contrast in infer-
ences presented here between the tested sample and the
entire cohort highlights the value of appropriate handling
of missing data in informing clinical practice and policy.
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